Policy Boost Fuels Cell Therapy Innovation: Shanghai Strengthens CAR-T Regulation as Pioneering Companies Advance Clinical Pipelines
Juventas
Innovative Cell Therapy Drug Developer
On August 28, the Shanghai Municipal Medical Products Administration issued the "Shanghai Regulations on the Supervision and Management of Autologous Chimeric Antigen Receptor T-Cell (CAR-T)" (hereinafter referred to as the "CAR-T Management Regulations"). It is reported that the original interim regulations will expire on August 31, 2024. The new regulations will "seamlessly connect," and while becoming formal regulations, they also provide a reference for the post-marketing supervision and management of other types of cell therapy drugs in Shanghai.
The validity period of the "CAR-T Management Regulations" has also been amended from "2 years" to "5 years," and will be implemented starting from September 1, 2024, ensuring seamless continuity with the original document.
Shanghai Municipal Medical Products Administration revealed that the revision of the "CAR-T Management Regulations" mainly takes into account that the cell therapy pharmaceuticals industry has become an important "new track," and Shanghai is one of the most dynamic cell and gene therapy industry clusters in China. Currently, China has approved the market launch.5 China-produced CAR-T drugs, among whichOne China-produced CAR-T drug, Yuan Ruida® (Najiaolun Race Injection, CNCT19), is the first core product independently developed by Juventas, located in Xingbei Free Trade No.1.。
The product was officially approved for marketing by the National Medical Products Administration in November 2023, a significant milestone not only in the field of leukemia treatment in China.The First CAR-T Drug, which is also a fully independent innovation in China.The First CD19 CAR-T DrugJuventas has deeply cooperated with top national institutions in China, establishing an international new drug research and development system centered on technology platforms such as CAR, iPSCs, and gene editing. It has over 10 pipeline products under research and development, covering diseases including hematologic tumors, solid tumors, and autoimmune diseases.
▲ Juventas R&D Pipeline (Source: Official Website)
Xingbei·FTO integrates comprehensive resource advantages to provide truly in-depth technical incubation for innovative companies in the cell therapy field, and is committed to building an international biomedical industry innovation and entrepreneurship base. Besides,JuventasThe park is home to a number of leading companies in the cell therapy field, includingStellar BioPharma, Westlake BioPharma, LeapCell BioPharmaetc.
StellarCyte Bio is an innovative biopharmaceutical company focused on developing next-generation immune cell products using iPSC-derived CAR-NK technology.
Neostem Biotech values original innovation, building a highly efficient and productive modular product development technology platform to effectively advance product development.
▲iPSC-CAR-NK Technology Pathway Diagram(Image Source:Official Website)
Xingyi Ang Biotechnology's process advantage lies in the development of a unique iNK efficient differentiation and expansion process, achieving GMP-standard industrialized, large-scale production.
▲Characteristics of iNK Preparation Process(Image Source:Official Website)
Westlake Bio innovatively developed a world-leading engineered red blood cell technology platform.REDx, leveraging the natural enrichment of red blood cells in immune organs, they are engineered to possess the ability to activate immune cells.
Westlake BioHave been deployed in multipleFirst-in-ClassCell therapy R&D pipeline, targeting major diseases such as cancer, immunity, and metabolism. The first innovative achievementWTX-212Has entered the clinical trial stage, in patients with end-stage solid tumors resistant to immunotherapy,WTX-212Monotherapy demonstrated excellent efficacy and safety, and for the first time achieved complete remission with erythrocyte drugs in patients with solid tumors. Currently, Westlake Bio has preliminarily established a highly automated "All-in-One"Red Blood Cell Drug Production Line, PossessingGMPThe pilot production workshop can meet the clinical needs of a large number of patients.
▲ R&D Pipeline (Image Source: Official Website)
Yosemite Biosciences is a global leader in human pluripotent stem cell-derived neurological disease cell therapies. Established in 2021, the company has a research and development center and GMP cleanroom facility totaling approximately 4,000 square meters, located in Phase II of the FTZ Life Science Park in the Shanghai Free Trade Zone.
Yuesai Bio has developed four highly innovative and integrated technology platforms, including a reprogramming technology platform, a stem cell differentiation platform, the SISBAR lineage tracing technology, and a high-precision gene editing platform, which can research and produce neural cell drugs with higher purity and more stable efficacy, achieving efficient and safe clinical treatment outcomes.
Juventas' First Pipeline — For the Treatment ofParkinson's DiseaseThe midbrain dopamine-producing neural precursor cell drug is currently rapidly advancing in IIT trials as well as registrational clinical trials.
▲ R&D Pipeline (Image Source: Official Website)
Cell therapy drugs are currently in the spotlight, undaunted by the so-called winter of the innovative drug industry. As an important member of the innovative drug industry base, Star North · FTI No.1 will continue to play a key role in this industrial chain, providing a solid foundation and ample space for the development of innovative drug companies in the cell therapy field. We believe that, with the strong support and favorable policies from the state, China's innovative drug industry will surely embrace a more brilliant development prospect.
About SimbayPark
Shanghai FT1 Life Science Park (Abbreviation"Simbay Park, Star North · Free Trade No.1") is located in the Waigaoqiao Bonded Area, the core of Shanghai's Pudong New Area Free Trade Zone. It is an innovative service-oriented characteristic industrial park under the Star North Group, focusing on the incubation, cultivation, and transformation of medical enterprises.The park relies on the unique advantages of an outward-oriented economic zone with "Free Trade + Bonded" characteristics. By gathering the full range of service resources for the biomedical industry’s CRO+CDMO+CSO+EHS, government innovation and entrepreneurship support policies, and numerous well-known investment institutions, it provides enterprises with in-depth technical incubation within the medical industry. Acting as a steward for corporate technology transfer and transformation, it is committed to building an international biomedical industry innovation and entrepreneurship base.
